<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02206230</url>
  </required_header>
  <id_info>
    <org_study_id>BR-02-1401</org_study_id>
    <nct_id>NCT02206230</nct_id>
  </id_info>
  <brief_title>Trial of Hypofractionated Radiation Therapy for Glioblastoma</brief_title>
  <official_title>A Randomized Controlled Trial of Conventional Versus Hypofractionated Radiation Therapy With Temozolomide for Patients With Newly Diagnosed Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHS Cancer Control Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cross Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to compare standard radiation therapy with hypofractionated&#xD;
      radiation therapy for patients with newly diagnosed glioblastoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypofractionated radiation therapy (RT) in the treatment of patients with glioblastoma, 18 -&#xD;
      70 years of age with good performance status (ECOG 0 - 2), will be well tolerated and yield&#xD;
      survival non-inferior to conventional fractioned RT, allowing significant abbreviation of the&#xD;
      length of the radiation course required for these patients with limited survival. The&#xD;
      importance of hypofractionation is, therefore, not in improving survival, but rather to&#xD;
      shorten RT duration to improve patient comfort and convenience. This approach is pertinent&#xD;
      given the limited life expectancy of glioblastoma and has been used in patients with&#xD;
      prolonged survival including breast and prostate cancers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 24 months from date of randomization to date of death due to any cause</time_frame>
    <description>Patients without an event will be censored the last time they were known to be alive</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 24 month where PFS is defined as the time between randomization and radiographic progression based on RECIST criteria or death due to any cause.</time_frame>
    <description>Patients without an event will be assessed at the date of last follow-up for progression. Patients with no post-baseline follow-up for progression will be censored at the day of randomization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Hypofractionated radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated radiation therapy of 60 Gy in 20 fractions (3 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week. After a 4-week break, temozolomide days 1-5 every 28 days for 6 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard radiation therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard radiation therapy of 60 Gy in 30 fractions (2 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week. After a 4-week break, temozolomide days 1-5 every 28 days for 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated radiation therapy</intervention_name>
    <arm_group_label>Hypofractionated radiation therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard radiation therapy</intervention_name>
    <arm_group_label>Standard radiation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed, histologically proven intracranial glioblastoma or gliosarcoma&#xD;
&#xD;
          -  History and physical exam within 14 days prior to randomization&#xD;
&#xD;
          -  Between 18 and 70 years of age&#xD;
&#xD;
          -  ECOG 0 - 2&#xD;
&#xD;
          -  Stable or decreasing dose of corticosteroids for at least 14 days prior to&#xD;
             randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior invasive malignancy unless disease free for &gt; 3 years&#xD;
&#xD;
          -  Prior head or neck RT (except for glottic cancer) or systemic therapy precluding&#xD;
             delivery of concurrent and adjuvant temozolomide&#xD;
&#xD;
          -  Treatment with any other therapeutic clinical protocol within 30 days prior to study&#xD;
             registration or during participation in the study&#xD;
&#xD;
          -  Specific severe, active co-morbidities&#xD;
&#xD;
          -  Not willing or able to use medically acceptable forms of contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cross Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samir Patel, MD</last_name>
    <phone>780-432-8783</phone>
    <email>samir.patel2@albertahealthservices.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Patel, MD</last_name>
      <phone>780-432-8518</phone>
      <email>samir.patel2@albertahealthservices.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>July 24, 2014</study_first_submitted>
  <study_first_submitted_qc>July 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2014</study_first_posted>
  <last_update_submitted>December 31, 2015</last_update_submitted>
  <last_update_submitted_qc>December 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glioblastoma</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>hypofractionated radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

